Oruka Therapeutics Signs Material Definitive Agreement
Ticker: ORKA · Form: 8-K · Filed: Dec 19, 2024 · CIK: 907654
| Field | Detail |
|---|---|
| Company | Oruka Therapeutics, Inc. (ORKA) |
| Form Type | 8-K |
| Filed Date | Dec 19, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $22.0 million, $1.5 million, $2.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, definitive-agreement
TL;DR
Oruka Therapeutics just signed a big deal, details TBD.
AI Summary
Oruka Therapeutics, Inc. entered into a Material Definitive Agreement on December 17, 2024. The filing does not disclose the specific details of this agreement, only that it is a significant contract for the company.
Why It Matters
This filing indicates a significant new contract for Oruka Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details about the material definitive agreement introduces uncertainty regarding its terms and potential impact.
Key Players & Entities
- Oruka Therapeutics, Inc. (company) — Registrant
- December 17, 2024 (date) — Date of Earliest Event Reported
- Delaware (jurisdiction) — State of Incorporation
- ARCA biopharma, Inc. (company) — Former Company Name
- NUVELO INC (company) — Former Company Name
- HYSEQ INC (company) — Former Company Name
FAQ
What is the nature of the Material Definitive Agreement entered into by Oruka Therapeutics?
The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on December 17, 2024.
When was the Material Definitive Agreement reported to be effective?
The earliest event reported, which includes the entry into the Material Definitive Agreement, was on December 17, 2024.
What is Oruka Therapeutics, Inc.'s state of incorporation?
Oruka Therapeutics, Inc. is incorporated in Delaware.
Has Oruka Therapeutics, Inc. operated under any former names?
Yes, Oruka Therapeutics, Inc. has operated under the former names ARCA biopharma, Inc., NUVELO INC, and HYSEQ INC.
What is the SIC code for Oruka Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Oruka Therapeutics, Inc. is 2835, for In Vitro & In Vivo Diagnostic Substances.
Filing Stats: 718 words · 3 min read · ~2 pages · Grade level 14.2 · Accepted 2024-12-19 07:16:40
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 Par Value ORKA The Nasdaq Global Ma
- $22.0 million — mpany is obligated to pay Paragon up to $22.0 million based on specific development, regulato
- $1.5 million — t to reach such milestones, including a $1.5 million fee for nomination of a development can
- $2.5 million — dy), and a further milestone payment of $2.5 million upon the first dosing of a human patien
Filing Documents
- ea0225145-8k_oruka.htm (8-K) — 33KB
- 0001213900-24-110303.txt ( ) — 203KB
- orka-20241217.xsd (EX-101.SCH) — 3KB
- orka-20241217_lab.xml (EX-101.LAB) — 33KB
- orka-20241217_pre.xml (EX-101.PRE) — 22KB
- ea0225145-8k_oruka_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Oruka Therapeutics, Inc. Date: December 19, 2024 By: /s/ Paul Quinlan Paul Quinlan General Counsel 2